Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI filing briefs · archive

8-K filings in July 2026, explained

1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

Clear

1 of 1,916 briefs matches

newest first · times in ET
PRMEPrime Medicine, Inc. Jul 8, 8:02 AM ET

Prime Medicine wins arbitration ruling against Beam over PM647 development candidate

Positive legal/regulatory Written later 8.01

An arbitration tribunal issued a final award on July 6, 2026, declaring that Prime Medicine's PM647 candidate for Alpha-1 Antitrypsin Deficiency is within the agreement's Field and that the company did not breach its 2019 agreement with Beam Therapeutics. The tribunal denied Beam's requests for damages and injunctive relief and denied the remaining claims by both parties. The ruling removes a breach claim tied to a key development candidate, though the filing gives no financial figures.

  • Final Award received July 6, 2026 from the arbitration tribunal in proceedings with Beam Therapeutics
  • Tribunal declared PM647, targeting Alpha-1 Antitrypsin Deficiency, is within the agreement's Field
  • Tribunal denied Beam's requests for damages and injunctive relief and denied remaining claims by both parties
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.